active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was explaining DNAP progress in testing responses on Ovarian cancer patients and couldn't find the PR. I remembered the PR but I couldn't find it on the DNAP site so here comes ann441 to the rescue... Thanks a million.
ifida, do you think they will follow through with the release today?
Thanks ann441 for those great posts.... I was able to forward them to a interested investor.
I am in complete agreement with you my man.... in fact I hope Ovenome news with a Hutton buy recommendation or something in that order next week would suit me fine.
To a better 2005 the break-out year!
I hope they held up the report at DNAP request so they can include some late breaking news...... C'mon DNAp
LAST DAY BASHERS... ENJOY!
Thanks W2p, that shows we will be partnering with other companies.
Very thoughtful posts frog.... thanks I enjoyed reading them.
IMHO, I'm afraid you are correct.
Ditto ifida.
Last year for whiners....... 2 MORE DAYS!
Yes, he did ann441.
Correct so we start with version (1.0) and advance from there.... DNAP has version 1 ------- I hope?
Amen chrisbaskett!
Good stuff Gcbr... opinions have shifted!
AFFX spreading the love: http://biz.yahoo.com/prnews/041228/sftu007_1.html
Where's the love for DNAP?
DRCAL I take it everyone agree DNAP will have a PR blitz in January 2005!
Yeah DRCAL, I'm trying to remember how I came to that conclusion..... there's a poster on the NAP HEADS board who would like to know?
Oh nooooooooo....... taxes on online purchases!http://story.news.yahoo.com/news?tmpl=story&cid=74&e=2&u=/cmp/20041224/tc_cmp/56200341
I like the way you said that.... let's hope!
Bashers holding their breaths fearful of the HUGE PRs coming our way!
TOOOOOOOOOOOOODAMOOOOOOOOOOOOOOON!
GGGGGGGGOOOOOOOOOOOOOOOOOOOOO DNAP!
The same way ORCH had to accept DNAP technology is the same reason BIG Pharma will..... economics 101 - DEMAND!
"We will be contacting as many agencies, police and investigators as possible over the next two to three weeks, right up to the last minute, to try and encourage investigators and grant submitters to include DNAWitness(TM) as a part of their grant proposals," said Zach Gaskin, Technical Coordinator of Forensics at DNAPrint genomics, Inc. "We are also encouraging grant applicants to use other DNA testing services, such as ReliaGene's Y-Chromosome STR test, that helped convict Derrick Todd Lee, and mitochondrial DNA testing. The current landscape of forensic DNA testing is changing and we simply want to make sure that investigators realize all the tools they have for identifying perpetrators. Grant funding will be a key element," Gaskin pointed out. "Every forensic sample in CODIS should be profiled using DNAWitness(TM), and those cold cases destined for CODIS are no different," he concluded.
ORCH wants piece of this pie:
DNAWitness(TM) is a novel investigative tool that could be used on the aforementioned 84,477 forensic profiles in CODIS, which represent the growing number of cold cases in the United States. DNAWitness(TM) has already had notable success in several cases, including a recent high profile case involving the Louisiana serial killer Derrick Todd Lee. Lee was captured two months after investigators received a report that the unknown perpetrator was 85% Sub-Saharan African and 15% Native American. This information helped change the focus of the investigation. Lee was convicted on August 11, 2004 for the murder of Geralyn Barr DeSoto. DNAPrint continues to encourage federal officials and policy makers to make DNAWitness(TM) the next logical step in criminal investigations when no matches are found in CODIS.
http://www.dnaprint.com/2003/pressreleases/pr_08_16_04.htm
ORCH stunning PR :
http://biz.yahoo.com/prnews/041214/phtu004_1.html
Press Release Source: Orchid BioSciences, Inc.
Orchid Cellmark to Distribute Innovative DNA-Based Law Enforcement Tool
Tuesday December 14, 7:00 am ET
-- DNAWitness(TM) Uses Crime Scene DNA to Help Identify the Physical Characteristics of Suspects --
PRINCETON, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - News), a leading worldwide supplier of identity DNA testing services, today announced an agreement to distribute DNAWitness(TM), a forensic service product developed and commercialized by DNAPrint genomics. DNAWitness enables criminal investigators to develop a profile of a suspect's likely general physical attributes using DNA recovered from the crime scene. Insight into these physical attributes is generated by proprietary algorithms in DNAWitness that make it possible to determine the proportions of European, East Asian, Native American and sub-Saharan African ancestry indicated by the suspect's DNA. DNAWitness has already demonstrated its utility as a crime- fighting tool in a number of high profile cases. Financial terms of the one- year, non-exclusive distribution agreement with DNAPrint genomics were not disclosed.
"With Orchid's long-established role as a leading provider of DNA testing services to criminal justice agencies in the U.S. and Europe, DNAWitness is a logical addition to the forensic services toolbox we offer our clients," said Mark Stolorow, executive director of Orchid Cellmark. "Our commitment to scientific innovation in the application of DNA to solving crimes made us among the first to realize the potential of SNPs, or single nucleotide polymorphisms, to address unmet needs in identity testing. We are now pleased to offer our police department customers this unique SNP-based product to help them identify the likely physical characteristics of the perpetrators of the many serious unsolved crimes where the suspect's DNA does not match any of the convicted offender DNA profiles already on file in state and federal databases."
DNAWitness has been used successfully in a number of investigations, including a recent case involving the now-convicted Louisiana serial killer Derrick Todd Lee. Information on Lee's ancestry helped change the focus of the investigation of a spate of serial murders in the region, leading to his arrest and subsequent conviction. Law enforcement agencies using the DNAWitness service receive the ancestry profile generated by the suspect's DNA and a photographic database of volunteers that provides examples of people with similar ancestry profiles, as well as identifying information for the case.
Under the Cellmark brand, Orchid has been a leader in private forensic DNA analysis since 1987 and is now one of the largest private DNA forensic testing providers in the world. Orchid has an international network of forensic testing laboratories in the U.S. and U.K., where it works with the famed "Scotland Yard" and others. The company provides a full range of high quality, customized forensic DNA testing and consultative services for both prosecutors and defendants. Its services include DNA testing for criminal casework analysis and expert testimony, as well as identification of victims of accidents and disasters. Last year the company launched DNA Express(TM), a premium service to help U.S. local law enforcement agencies analyze backlogs of DNA evidence from unsolved crimes in five business days, as compared to the standard one-to-two months. More information on DNAWitness and Orchid's U.S. forensic DNA testing services can be found at http://www.orchidcellmark.com.
About Orchid BioSciences
Orchid BioSciences is a leading provider of identity genetics services for the forensic and paternity DNA testing markets and for public health and animal DNA testing for food safety. Orchid's strong market positions in these segments leverage the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world- renowned Cellmark and GeneScreen brands that have been associated with exceptional quality, reliability, innovation and customer service for nearly two decades. More information on Orchid can be found at http://www.orchid.com.
DNAWitness is a trademark of DNAPrint genomics.
DNAExpress is a trademark of Orchid BioSciences.
All statements in this press release that are not historical are forward- looking statements within the meaning of Private Securities Litigation Reform Act of 1995, including statements regarding: the expected ability of DNAWitness to help criminal investigators and police departments identify physical attributes and characteristics of suspects and perpetrators. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid products and services, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, patent protection, litigation and Orchid's ability to obtain additional financing. These risks and other additional factors affecting Orchid's business are discussed under the headings "Risks Related to Our Business," "Risks Related to the Biotechnology Industry" and "Risks Associated with Our Common Stock" in Orchid's Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission, and in other filings made by Orchid with the Securities and Exchange Commission from time to time. Orchid expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.
------------------------------------------------------------------------
Source: Orchid BioSciences, Inc.
You are........ INVESTING VISIONARIES
I remember that article..... I seem to remember DNAP couldn't get the quality samples they needed from that Co.
Yeah, I like that..... it sounds reasonable.
That's beautiful.... make it so!
Hopefully this will be the end of these low prices.
Yeah, that is a thought.......... isn't it?
Can you believe this?..... YES
http://biz.yahoo.com/ap/041221/ye_pharmaceuticals_4.html
No touchdown but we are beginning to see a momentum shift of public and government opinion of adverse drug reactions.... DNAP day is getting closer!
GOOOOOOOOOOOOOOOOO DNAP!
Questions-Questions-Questions???
http://story.news.yahoo.com/news?tmpl=story&cid=679&e=1&u=/usatoday/20041220/cm_usatoday...
IMHO-I don't think you have the time to do both.
$5.00
Everybody is getting in on the act: http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh40188_2004-12-17_22-54-42_wat...
CBS 48 hours thought....... I agree with you DNAP is involved but if DNAP were to release a PR concerning that show it will steal the thunder. That will be a good PR for Monday morning.
Oh well, I'm through imitating my heroes on this board with links.
They need the unbiased answers DNAP will give:
http://story.news.yahoo.com/news?tmpl=story&cid=676&e=3&u=/usatoday/20041217/ts_usatoday...
DNAP to the rescue..... one day.